Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $0.82 on Tuesday. The firm has a fifty day moving average of $0.89 and a two-hundred day moving average of $1.12. Bio-Path has a one year low of $0.59 and a one year high of $9.99.

Institutional Investors Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by institutional investors and hedge funds.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.